Early prediction of histopathological tumor response to preoperative chemotherapy by Tc-99m MIBI imaging in bone and soft tissue sarcomas

Clinical Nuclear Medicine

Volumn 35, Issue 3, 2010, Pages 154-159

  Taki, Junichi ^a   Inaki, Anri ^b   Wakabayashi, Hiroshi ^b   Sumiya, Hisashi ^a   Tsuchiya, Hiroyuki ^c   Zen, Yoh ^a   Kinuya, Seigo ^b  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^b Department of Biotracer Medicine ^*  (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

Bone and soft tissue sarcoma; Ewing sarcoma; Osteosarcoma; Preoperative chemotherapy; Tc 99m MIBI; Treatment monitoring

Indexed keywords

CAFFEINE; CISPLATIN; DOXORUBICIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER SURGERY; CHILD; CONTINUOUS INFUSION; FEMALE; GAMMA SCINTIGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OSTEOSARCOMA; PREDICTION; PREOPERATIVE TREATMENT; SCHOOL CHILD; SCINTIANGIOGRAPHY; SENSITIVITY AND SPECIFICITY; SOFT TISSUE SARCOMA; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; BONE NEOPLASMS; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; PREOPERATIVE PERIOD; PROGNOSIS; ROC CURVE; SARCOMA; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M SESTAMIBI; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77649098506     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3181cc637d     Document Type: Article

References (38)

1. Tsuchiya H, Tomita K, Minematsu K, et al. Limb salvage using distraction osteogenesis. A classification of the technique. J Bone Joint Surg Br. 1997;79:403-411.
2. Tsuchiya H, Tomita K, Mori Y, et al. Marginal excision for osteosarcoma with caffeine assisted chemotherapy. Clin Orthop. 1999;358:27-35.
3. Jaffe N, Patel SR, Benjamin RS. Chemotherapy in osteosarcoma. Basis for application and antagonism to implementation; early controversies surrounding its implementation. Hematol Oncol Clin North Am. 1995;9:825-840.
4. Eilber FR, Morton DL, Eckardt J, et al. Limb salvage for skeletal and soft tissue sarcomas. Multidisciplinary preoperative therapy. Cancer. 1984;53: 2579-2584.
5. Wunder JS, Paulian G, Huvos AG, et al. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am. 1998;80:1020-1033.
6. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in highgrade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776-790.
7. Caner B, Kitapcl M, Unlu M, et al. Technetium-99m-MIBI uptake in benign and malignant bone lesions: a comparative study with technetium-99m-MDP. J Nucl Med. 1992;33:319-324.
8. Taki J, Sumiya H, Tsuchiya H, et al. Evaluating benign and malignant bone and soft-tissue lesions with technetium-99m-MIBI scintigraphy. J Nucl Med. 1997;38:501-506.
9. Buscombe JR, Cwikla JB, Thakrar DS, et al. Scintigraphic imaging of breast cancer: a review. Nucl Med Commun. 1997;18:698-709.
10. Taki J, Sumiya H, Asada N, et al. Assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy. J Nucl Med. 1998;39:1179-1184.
11. Burak Z, Ersoy O, Moretti JL, et al. The role of Tc-99m-MIBI scintigraphy in the assessment of MDR1 overexpression in patients with musculoskeletal sarcomas: comparison with therapy response. Eur J Nucl Med. 2001;28: 1341-1350.
12. Soderlund V, Larsson SA, Bauer HC, et al. Use of 99mTc-MIBI scintigraphy in the evaluation of the response of osteosarcoma to chemotherapy. Eur J Nucl Med. 1997;24:511-515.
13. Moustafa H, Riad R, Omar W, et al. 99mTc-MIBI in the assessment of response to chemotherapy and detection of recurrences in bone and soft tissue tumors of the extremities. Q J Nucl Med. 2003;47:51-57.
14. Taki J, Higuchi T, Sumiya H, et al. Prediction of final tumor response to preoperative chemotherapy by Tc-99m MIBI imaging at the middle of chemotherapy in malignant bone and soft tissue tumors: comparison with Tl-201 imaging. J Orthop Res. 2008;26:411-418.
15. Tsuchiya H, Tomita K, Mori Y, et al. Marginal excision for osteosarcoma with caffeine assisted chemotherapy. Clin Orthop. 1999;358:27-35.
16. Taki J, Sumiya H, Higuchi T, et al. Prediction of myocutaneous adverse side effect due to intra-arterial chemotherapy by intra-arterial 99mTc-macroaggregated albumin administration in patients with bone and soft-tissue tumors. J Nucl Med. 2002;43:1452-1456.
17. Metz CE. Some practical issues of experimental design and data analysis in radiological ROC studies. Invest Radiol. 1989;24:234-245.
18. Metz CE, Herman BA, Shen JH. Maximum likelihood estimation of receiver operating characteristic (ROC) curves from continuously-distributed data. Stat Med. 1998;17:1033-1053.
19. McNeil BJ, Keller E, Adelstein SJ. Primer on certain elements of medical decision making. N Engl J Med. 1975;293:211-215.
20. Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation. 1990;82:1826-1838.
21. Beanlands RS, Dawood F, Wen WH, et al. Are the kinetics of technetium-99m methoxyisobutyl isonitrile affected by cell metabolism and viability? Circulation. 1990;82:1802-1814.
22. Carvalho PA, Chiu ML, Kronauge JF, et al. Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat hearts. J Nucl Med. 1992;33:1516-1522.
23. Delmon-Moigeon LI, Piwnica-Worms D, Van den Abbeele AD, et al. Uptake of the cation hexakis(2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro. Cancer Res. 1990;50:2198-2202.
24. Maublant JC, Zhang Z, Rapp M, et al. In vitro uptake of technetium-99mteboroxime in carcinoma cell lines and normal cells: comparison with technetium-99m-sestamibi and thallium-201. J Nucl Med. 1993;34:1949-1952.
25. Uhl M, Saueressig U, van Buiren M, et al. Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusionand perfusion-weighted magnetic resonance imaging. Invest Radiol. 2006;41: 618-623.
26. Dyke JP, Panicek DM, Healey JH, et al. Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology. 2003;228:271-278.
27. Kajihara M, Sugawara Y, Sakayama K, et al. Evaluation of tumor blood flow in musculoskeletal lesions: dynamic contrast-enhanced MR imaging and its possibility when monitoring the response to preoperative chemotherapy-work in progress. Radiat Med. 2007;25:94-105.
28. Ongolo-Zogo P, Thiesse P, Sau J, et al. Assessment of osteosarcoma response to neoadjuvant chemotherapy: comparative usefulness of dynamic gadolinium-enhanced spin-echo magnetic resonance imaging and technetium-99m skeletal angioscintigraphy. Eur Radiol. 1999;9:907-914.
29. Bramer JA, Gubler FM, Maas M, et al. Colour Doppler ultrasound predicts chemotherapy response, but not survival in paediatric osteosarcoma. Pediatr Radiol. 2004;34:614-619.
30. Schulte M, Brecht-Krauss D, Werner M, et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med. 1999;40:1637-1643.
31. Iagaru A, Masamed R, Chawla SP, et al. F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas. Clin Nucl Med. 2008;33:8-13.
32. Jones DN, McCowage GB, Sostman HD, et al. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J Nucl Med. 1996;37:1438-1444.
33. Hawkins DS, Rajendran JG, Conrad EU III, et al. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography. Cancer. 2002;94:3277-3284.
34. Benz MR, Evilevitch V, Allen-Auerbach MS, et al. Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors. J Nucl Med. 2008;49:1038-1046.
35. Soderlund V, Larsson SA, Bauer HC, et al. Use of 99mTc-MIBI scintigraphy in the evaluation of the response of osteosarcoma to chemotherapy. Eur J Nucl Med. 1997;24:511-515.
36. Moustafa H, Riad R, Omar W, et al. 99mTc-MIBI in the assessment of response to chemotherapy and detection of recurrences in bone and soft tissue tumors of the extremities. Q J Nucl Med. 2003;47:51-57.
37. Piwnica-Worms D, Chiu ML, Budding M, et al. Functional imaging of multidrug-resistant P-Glycoprotein with an organotechnetium complex. Cancer Res. 1993;53:977-984.
38. Burak Z, Moretti JL, Ersoy O, et al. 99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression. J Nucl Med. 2003;44:1394-1401.